Genzyme begins shipping Fabrazyme from newly approved Framingham manufacturing plant
1 March 2012 | By Sanofi
Genzyme has begun shipping Fabrazyme® (agalsidase beta)...
List view / Grid view
News
Mergers and acquisitions
29 February 2012 | By Helen Difford, Editor of European Pharmaceutical Review
Helen Difford, Editor of European Pharmaceutical Review, looks at the reasons behind recent mergers and acquisitions within the pharmaceutical sector...
Boehringer Ingelheim expands capabilities
29 February 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has expanded its biopharmaceutical development & manufacturing capabilities...
Intelligently dose chemical reactors at high flow rates with the Atlas Syringe Pump
29 February 2012 | By kdm communications limited
Syrris has created the unique Atlas Syringe Pump XL...
Brian McNamara named Division Head, Novartis OTC
29 February 2012 | By Novartis
Novartis named Brian McNamara to the position of Division Head of Novartis OTC (Over-the-Counter), effective immediately...
U.S. FDA extends action date for ELIQUIS® (apixaban) by three months
29 February 2012 | By Pfizer
The U.S. FDA has extended the action date by three months for the NDA for Eliquis® (apixaban)...
Abbott and Galapagos announce global collaboration for novel oral therapy, GLPG0634, in Phase II
29 February 2012 | By Abbott
Abbott and Galapagos have entered into a global collaboration...
Two Phase III studies of Novartis drug INC424 published in NEJM show significant clinical benefit for patients with myelofibrosis
29 February 2012 | By Novartis
Results of the COMFORT-I and COMFORT-II trials show INC424 significantly reduced disease burden in patients with myelofibrosis...
Lilly introduces global ‘Innovation Starts Here’ initiative to foster innovation and quality science
28 February 2012 | By Eli Lilly and Company
Lilly award programs also further research and development investment in Europe...
FDA approves AVONEX PEN and dose titration regimen
28 February 2012 | By
Dosing enhancements may improve treatment experience for patients receiving AVONEX® (interferon beta-1a) for MS...
Biogen Idec submits application to FDA for approval of oral BG-12 to treat multiple sclerosis
28 February 2012 | By Biogen Idec
EMA submission anticipated within the coming days...
Amgen and European Schoolnet launch new professional development initiative for life science teachers
28 February 2012 | By Amgen
Amgen & European Schoolnet launched “Amgen Science Teacher Training Initiative”...
Ranbaxy crosses $2bn in global sales
28 February 2012 | By Daiichi Sankyo Co., Ltd
The Board of Directors of Ranbaxy Laboratories Limited, took on record the audited results for the Quarter and Year ended December 31, 2011...
Bristol-Myers Squibb and Duke Translational Medicine Institute form strategic relationship to broaden interactions
28 February 2012 | By Bristol-Myers Squibb Company
First project will be to develop and implement protocol for Phase II study in IPF...
Lundbeck strengthens ownership of desmoteplase by acquiring Paion’s remaining rights
28 February 2012 | By H. Lundbeck A/S (Lundbeck)
Lundbeck acquires Paion's remaining rights to desmoteplase for EUR 20.1 million thereby further strengthening the control over desmoteplase...
